ArticleSAGE open medical case reports2025
Photorefractive keratectomy in a patient with Stargardt disease: Case report.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case presents a successful outcome following photorefractive keratectomy surgery in a patient with Stargardt disease. A 23-year-old female with a history of Stargardt disease oculus uterque and high myopia oculus uterque presented for refractive surgery evaluation. The patient underwent photorefractive keratectomy oculus uterque. Before surgery, the patient's refraction was -6.00 diopters oculus uterque. Visual acuity was 20/200 with correction oculus uterque. After photorefractive keratectomy, visual acuity improved to 20/100 oculus uterque without correction at 7 days post-op. At 1 year post-op, visual acuity remained stable at 20/100 +1 oculus dexter and 20/200 +1 oculus sinister without correction. Electroretinography pre- and postoperatively was stable. The patient reported subjective improvement in vision at all time points after the procedure, likely due to the resolution of minification from previous corrective lenses. While photorefractive surgery is not a definitive treatment for Stargardt disease, Stargardt disease is not a contraindication for photorefractive keratectomy surgery. This case presents successful refractive correction without retinal complications. We suggest that performing photorefractive keratectomy in a patient with Stargardt disease is unlikely to cause harm due to disease exacerbation based on this study and previous studies on the interaction of photorefractive keratectomy with corneal, lens, and retinal level outcomes. Though a soft visual endpoint may pose a unique challenge for refractive surgery in Stargardt disease, we report effective use of the iDesign 2.0 software. In all, we postulate that refractive surgery such as photorefractive keratectomy is likely to improve quality of life and vision in patients with Stargardt disease and possibly other inherited retinal pathologies as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.